Study of the Efficacy of Dienogest in the Treatment of Uterine Leiomyomas When Compared to Desogestrel and Goserelin

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2012 by University of Sao Paulo.
Recruitment status was  Not yet recruiting
Information provided by (Responsible Party):
LUIZ GUSTAVO OLIVEIRA BRITO, University of Sao Paulo Identifier:
First received: November 23, 2012
Last updated: November 27, 2012
Last verified: November 2012
The investigators´aim is to assess whether the progestagen dienogest reduces leiomyoma volume and its associated symptoms to the same extent as gonadotropin releasing hormone (GnRH) analogs or the progestagen desogestrel or whether it is inferior to other drugs already in use.

Condition Intervention Phase
Uterine Leiomyoma
Drug: Dienogest
Drug: Goserelin
Drug: Desogestrel
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Abnormal Uterine Bleeding in Women With Uterine Leiomyomas: Open Randomized Clinical Trial Of Non Inferiority Between Oral Dienogest, Oral Desogestrel and Subcutaneous Goserelin

Resource links provided by NLM:

Further study details as provided by University of Sao Paulo:

Primary Outcome Measures:
  • Leiomyoma Volume [ Time Frame: After 6 months of medical therapy ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Pictorial Blood Assessment Chart (PBAC) Score Reduction [ Time Frame: After 6 months of medical therapy ] [ Designated as safety issue: No ]
  • Number of episodes of vaginal bleeding [ Time Frame: After 6 months of medical therapy ] [ Designated as safety issue: No ]

Estimated Enrollment: 63
Study Start Date: January 2013
Estimated Study Completion Date: December 2013
Estimated Primary Completion Date: August 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Dienogest
Dienogest 2mg pills daily during 6 months
Drug: Dienogest
Dienogest 2mg pills daily during 6 months
Other Names:
  • Allurene
  • Visanne
Experimental: Goserelin
Goserelin 10.8mg preloaded syringe subcutaneously at the start of the study and after 3 months
Drug: Goserelin
Goserelin 10.8mg preloaded syringe subcutaneously at the start of the study and after 3 months
Other Name: Zoladex
Active Comparator: Desogestrel
Desogestrel 75mcg pills daily during six months
Drug: Desogestrel
Desogestrel 75mcg pills daily during six months
Other Name: Cerazette

Detailed Description:
Uterine leiomyoma is a very prevalent condition among women and, although it is mainly asymptomatic, it may be related to bothersome or debilitating symptoms, such as uterine bleeding and pelvic pain or pressure. The standard treatment is surgical (hysterectomy or myomectomy), but there has been continued interest on medical treatments. Progestagens have long been used to control bleeding associated to leiomyomas, but they have not been able to decrease myoma volume. GnRH analogs are well stablished agents, capable of controlling symptoms and decreasing the tumors´volume, but their use is limited by bone loss and menopausal symptoms. A newly introduced progestagen, dienogest, has been studied to treat endometriosis, but its effects on leiomyoma are only starting to be assessed. The investigators are aiming to compare dienogest with the GnRH analog goserelin and the progestagen desogestrel in a randomized trial to see how this new treatment compares with previously used drugs and whether it is similar, inferior or superior to them on controlling leiomyoma associated symptoms and decreasing leiomyoma volume.

Ages Eligible for Study:   35 Years to 55 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Women with 35 - 55 years of age
  • Uterine volume between 50cc and 500cc
  • Abnormal uterine bleeding probably associated to intramural uterine leiomyomas

Exclusion Criteria:

  • Pregnancy
  • Liver or kidney dysfunction
  • Women with only submucosal or subserosal uterine leiomyomas
  • Women with contraindications to any of the drugs (categories 3 and 4 of WHO eligibility criteria)
  • Use of anticoagulants
  • Others causes of abnormal uterine bleeding (endometrial pathology, cervical pathology)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01738724

Contact: Luiz Gustavo O Brito, MD, PhD +551636021000
Contact: Rafael M Moroni, MD +551636021000

Sponsors and Collaborators
University of Sao Paulo
Study Chair: Luiz Gustavo O Brito, MD, PhD FMRP-USP
  More Information

Responsible Party: LUIZ GUSTAVO OLIVEIRA BRITO, Assistant Physician, MD, PhD, University of Sao Paulo Identifier: NCT01738724     History of Changes
Other Study ID Numbers: FMRPUSP-UROGIN-002 
Study First Received: November 23, 2012
Last Updated: November 27, 2012
Health Authority: Brazil: National Committee of Ethics in Research

Additional relevant MeSH terms:
Connective Tissue Diseases
Neoplasms by Histologic Type
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms, Muscle Tissue
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Contraceptive Agents
Contraceptive Agents, Female
Contraceptive Agents, Male
Contraceptives, Oral
Contraceptives, Oral, Synthetic
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Reproductive Control Agents processed this record on May 24, 2016